New pill timing may help heart failure patients flush salt after meals

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 18 years or older. * Informed Consent: Willing and able to sign the informed consent form. * Stable Chronic HF: A clinical diagnosis of chronic heart failure considered stable by the patient's cardiologist/physician or another experienced clinician for at least one month prior to randomization. * Current Diuretic Therapy: Receiving an oral dose of 20 mg to 80 mg daily of furosemide, or 10 mg to 40 mg daily dose of torsemide, or 1 mg to 4 mg daily dose of bumetanide, for about 30 days prior to randomization. * Stable HF Medications: No anticipated changes in HF medications during the study period. * Female Participants: Premenopausal women of childbearing potential must have a negative pregnancy test prior to study initiation and agree to use effective contraceptive methods throughout the study period. Exclusion Criteria: * Other Diuretics: Requirement for a diuretic other than furosemide, bumetanide, or torsemide (except for spironolactone, eplerenone, finerenone, or SGLT2 inhibitors) at randomization or during the study. * Recent Cardiovascular Events: Myocardial infarction, stroke, transient ischemic attack, acute kidney injury, or acute HF requiring hospitalization within 30 days prior to randomization. * Severe Lung Disease: Severe or symptomatic lung disease or respiratory symptoms distinct from HF. * Urinary Issues: History of urinary incontinence, or inability to empty the bladder. * Uncontrolled Comorbidities: Uncontrolled diabetes mellitus or hypertension. * Renal Dysfunction: Estimated GFR \< 30 ml/min/1.72m². * Cardiac Conditions: History of flash pulmonary edema or amyloid cardiomyopathy. * Breastfeeding: Female participants who are breastfeeding. * Recent Participation in Clinical Trials: Participation in another clinical trial within the last three months prior to randomization. * Requirements for treatment with a non-steroidal anti-inflammatory drug (except for Aspirin up to 200 mg as PRN daily). * Serum potassium concentration \<3.5 or \>5.5 mmol/L.